• Skip to primary navigation
  • Skip to main content
  • Skip to footer

LKT Labs

Biochemicals for Life Science Research

  • Products
    • New Products
    • Cancer Biology
    • Cardiovascular
    • Endocrine Signaling and Immunology
    • Metabolic and GI Pathology
    • Microbiology
    • Natural Products
    • Neuroscience
    • Peptides
    • Pharmaceutical Impurities and Derivatives
    • Stem Cell Modulators
  • Services
    • Custom Synthesis
    • Natural Product Isolation
    • Analytical Services
  • Int’l Distributors
  • Support
    • About LKT Labs
    • General Inquiry
    • Bulk Quote Request
    • Document Request
    • Technical Support
    • Catalog Request
    • Product Flyers
  • Contact Us
  • Cart
  • Login / Register
NMS-1286937

NMS-1286937

Product ID N5072
Cas No. 1034616-18-6
Purity ≥98%
Product Unit SizeCostQuantityStock
1 mg $142.80 In stock
5 mg $228.10 In stock
10 mg $346.10 Please Inquire
Bulk Quote

Quicklinks

  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Custom Order

Description

NMS-1286937 is an inhibitor of polo-like kinase 1 (PLK1) that is currently in clinical trials as a potential treatment for various cancers; it exhibits anticancer chemotherapeutic activity. In osteosarcoma cells, NMS-1286937 induces cell cycle arrest and apoptosis and inhibits cell growth. In animal models of acute myelogenous leukemia (AML), this compound increases survival time and decreases tumor cell infiltration. Additionally, NMS-1286937 inhibits cell proliferation and induces apoptosis, cell cycle arrest, and tumor regression in cellular and animal models of colon cancer.

Product Info

Cas No.

1034616-18-6

Purity

≥98%

Formula

C24H27F3N8O3

Formula Wt.

532.52

IUPAC Name

1-(2-Hydroxyethyl)-8-{[5-(4-methyl-1-piperazinyl)-2-(trifluoromethoxy)phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide

Synonym

NMS1286937, NMS-P937

Solubility

DMSO 42 mg/mL warmed (78.87 mM) Ethanol 10 mg/mL warmed (18.77 mM) Water Insoluble

Appearance

White to off white powder

Shipping and Storage

Store Temp

-20°C

Ship Temp

Ambient

Downloads

MSDS

N5072 MSDS PDF

Info Sheet

N5072 Info Sheet PDF

References

Sero V, Tavanti E, Vella S, et al. Targeting polo-like kinase 1 by NMS-P937 in osteosarcoma cell lines inhibits tumor cell growth and partially overcomes drug resistance. Invest New Drugs. 2014 Dec;32(6):1167-80. PMID: 25193492.

Casolaro A, Golay J, Albanese C, et al. The Polo-Like Kinase 1 (PLK1) inhibitor NMS-P937 is effective in a new model of disseminated primary CD56+ acute monoblastic leukaemia. PLoS One. 2013;8(3):e58424. PMID: 23520509.

Valsasina B, Beria I, Alli C, et al. NMS-P937, an orally available, specific small-molecule polo-like kinase 1 inhibitor with antitumor activity in solid and hematologic malignancies. Mol Cancer Ther. 2012 Apr;11(4):1006-16. PMID: 22319201.

Beria I, Bossi RT, Brasca MG, et al. NMS-P937, a 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivative as potent and selective Polo-like kinase 1 inhibitor. Bioorg Med Chem Lett. 2011 May 15;21(10):2969-74. PMID: 21470862.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • C5864

    Coptisine Chloride, synthetic

    Isoquinoline alkaloid found in a variety of pla...

    ≥98%
  • N6076

    N(p-Tosyl)-GPR-pNA

    Thrombin substrate used to measure thrombin act...

    ≥95%
  • P6004

    PP-242

    Dual mTORC1/mTORC2 inhibitor.

    ≥98%
  • C0044

    CAL101

    p110δ PI3K inhibitor.

    ≥99%
  • O9201

    Oxaliplatin

    Pt-based DNA cross-linker.

    ≥98%
  • N8662

    NVP-BGJ398

    FGFR inhibitor.

    ≥98%
  • C2468

    β-Calcitonin Gene Related Peptide, human

    Endogenous calcitonin-family peptide, involved ...

    ≥98%
  • C9610

    D-Cycloserine

    NMDA partial agonist, D-Ala-D-Ala ligase inhibi...

    ≥98%
  • A686164

    Arecaidine Hydrochloride

    mAChR agonist, selective for M2.

    ≥98%
  • P7103

    Praziquantel

    Alters membrane permeability and Ca2+ signaling...

    ≥98%
  • E6398

    EPZ-5676

    DOT1L HMT inhibitor.

    ≥98%
  • R5700

    Ro 61-8048

    Kynurenine 3-hydroxylase inhibitor.

    ≥99%
  • A5217

    trans-Anethole

    Phenylpropene derivative found in essential oil...

    ≥98%
  • B8277

    Butein

    Flavonoid found in Rhus verniciflua and Butea m...

    ≥99%
  • A0501

    Abamectin

    Macrocyclic lactone avermectin; GABA antagonist...

    ≥70%
  • A724091

    Asciminib

    Allosteric inhibitor

    ≥98%
  • T1644

    Telmisartan

    AT-II antagonist, PPARγ/δ modulator.

    ≥98%
  • A7462

    Aspartame

    Dipeptide ester, commercial sweetener.

    ≥98%
  • S0044

    Salbutamol Free Base

    β2-adrenergic agonist.

    ≥98%
  • A7203

    AS-703026

    MEK1/2 inhibitor.

    ≥98%

Footer

  • Contact Us
  • About Us
  • Site Map
  • Terms and Conditions
LKT Laboratories, Inc.
545 Phalen Blvd.
St. Paul MN, 55130

Ph: (888)-558-5227
Fax: (888)-558-7329

©2025 LKT Laboratories, All Rights Reserved - Products for research use only